Celgene halts trial of blood cancer drug

Celgene said it will discontinue a Phase III study of its blood cancer treatment Revlimid as a first-line treatment in elderly patients with B-cell chronic lymphocytic leukemia after it noticed more deaths in patients treated with Revlimid compared with patients taking chlorambucil. The FDA put the study on clinical hold last week. Celgene said it will examine data from the trial to determine whether the imbalance is due to factors such as age or comorbidities.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI